Seoul, South Korea

Hyokyoung Kwon

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Hyokyoung Kwon in Lipid Nanoparticle Technology

Introduction

Hyokyoung Kwon is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of drug delivery systems, particularly through his work on lipid nanoparticles. With a total of two patents to his name, Kwon's innovations are paving the way for advancements in gene therapy.

Latest Patents

Kwon's latest patents include "Ionizable lipid compounds, lipid nanoparticles comprising same and therapeutic uses thereof" and "Lipid nanoparticles for in-vivo drug delivery, and uses thereof." Both inventions focus on lipid nanoparticles designed for in vivo drug delivery, specifically targeting liver tissue. These nanoparticles exhibit excellent biocompatibility and are capable of delivering gene therapeutic agents with high efficiency. As a result, they hold great potential for applications in lipid nanoparticle-mediated gene therapy.

Career Highlights

Hyokyoung Kwon is associated with Enhancedbio Inc., where he continues to develop innovative solutions in the field of drug delivery. His work is characterized by a commitment to improving therapeutic outcomes through advanced technology.

Collaborations

Kwon collaborates with talented individuals such as Hyukjin Lee and Minjeong Kim, contributing to a dynamic research environment that fosters innovation.

Conclusion

Hyokyoung Kwon's contributions to lipid nanoparticle technology represent a significant advancement in drug delivery systems. His patents reflect a dedication to enhancing the efficacy of gene therapy, which could lead to transformative changes in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…